ReviewDrug design, development and therapy2026
Advances in Targeting the AGEs-RAGE Pathway for the Treatment of Diabetic Kidney Disease.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating the Effects and Potential Mechanisms of Astragalus Root Against Diabetic Nephropathy Based on Bioinformatics Analysis and In Vitro Validation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) represents the most severe microvascular complication of diabetes and is the leading cause of end-stage renal disease globally. Its pathogenesis is complex, and current treatments have limitations. Advanced glycation end products (AGEs) and AGEs receptor (RAGE), constitute a core mechanism driving DKD progression. AGEs accumulate abnormally in high-glucose environments. Upon activation, RAGE mediates oxidative stress, chronic inflammation, renal fibrosis, dysregulation of autophagy, and apoptosis through multiple signaling pathways, ultimately leading to damage to the glomerular filtration barrier and exacerbating renal injury from multiple dimensions. This paper aims to elucidate the role of the AGEs-RAGE pathway in DKD and systematically review therapeutic strategies targeting this pathway. These include AGEs antagonists, AGEs-RAGE axis modulators, RAGE ligand binding inhibitors, antibody-based therapeutics, and traditional Chinese medicine. Additionally, clinical studies of AGEs-RAGE axis-targeted drug therapies for DKD are analyzed. This paper provides theoretical foundations for developing novel therapeutic drugs in DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.